盐与没有盐在心力衰竭中的限制 一个审查
1Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
European journal of clinical investigation
|June 26, 2024
概括
严格的限制并没有减少心力衰竭患者的死亡率或住院病例. 虽然没有改善主要结果,但减少盐的摄入量可能会提供轻微的症状缓解和改善生活质量.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内部医学 内部医学
背景情况:
- 标准医疗建议长期以来一直建议心力衰竭患者减少,因为人们担心液体保留.
- 最近的研究和元分析已经质疑严格限制的好处,有些人建议潜在的危害.
研究的目的:
- 审查现有文献,并确定严格的限制在治疗心力衰竭患者中的有效性.
- 评估摄入量对心力衰竭死亡率,住院率和生活质量的影响.
主要方法:
- 一篇关于2000年至2023年间出版的PubMed索引文章的叙事综述.
- 搜索术语包括"心力衰竭"",盐"","和"摄入液体".
主要成果:
- 大多数随机试验都是小的和异质的;一个大型试验因徒劳而被停止.
- 没有重要的证据支持严重的限制会降低心力衰竭的死亡率或住院病例.
- 一些研究表明,生活质量和职能阶级可能会略有改善.
结论:
- 严格的限制似乎没有降低心力衰竭患者的发病率或死亡率.
- 可能会观察到症状的改善,但主要的临床结果仍然不受减少的影响.
相关概念视频
Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K


